MarketFriction

Gland Pharma Ltd

NSE GLAND · BSE 543245 · Pharmaceuticals
₹2,874.40 -0.86%
NSE close2026-10-01
52 week range1,573.60 - 3,042.00
Market cap₹49,333 Cr.
P/E43.1
IPO 2020 · +92% since Nifty 500Nifty Smallcap 50Nifty Smallcap 100Smallcap 250Nifty PharmaNifty Healthcare IndexNifty MNC Price band 20% Delivery 57.3%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,3731,5451,5371,4021,4061,3841,4251,5061,4871,6951,7431,800
Expenses1,0491,1891,1791,1371,1091,0241,0771,1381,1731,2601,2301,311
Operating Profit324356359264297360348368314435513489
OPM %24%23%23%19%21%26%24%24%21%26%29%27%
Other Income5337425160584458843911161
Interest6510662371284104
Depreciation811059392949696101106108109111
Profit before tax290283298218257299288313284362506435
Tax %33%32%35%34%36%32%35%31%35%28%28%27%
Net Profit194192192144164205187215184261367317
EPS in Rs11.7811.6511.688.739.9312.4211.3213.0811.1515.8722.2619.21
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,6333,4634,4013,6255,6655,6166,4316,725
Expenses1,6782,1612,8902,6004,3324,3484,8014,974
Operating Profit9551,3021,5101,0251,3331,2691,6301,751
OPM %36%38%34%28%24%23%25%26%
Other Income139135224184170214292296
Interest735726423326
Depreciation9599110147345378424434
Profit before tax9931,3351,6191,0551,1331,0631,4651,587
Tax %22%25%25%26%32%34%30%
Net Profit7739971,2127817726991,0271,129
EPS in Rs49.8860.9473.7547.4246.9042.4062.3568.49
Dividend Payout %0%0%0%0%43%42%32%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth%13%21%18%
Compounded Profit Growth%1%8%49%
Stock Price CAGR%-4%21%50%
Return on Equity%11%9%11%
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital16161616161616
Reserves3,6315,8877,1417,9428,7079,13410,341
Borrowings5554372314284
Other Liabilities4355886718141,5151,7081,807
Total Liabilities4,0866,4967,8348,77810,61111,17312,449
Fixed Assets9689541,5021,5713,9474,1474,492
CWIP188338191177238151342
Investments001550000
Other Assets2,9295,2045,9867,0306,4266,8757,614
Total Assets4,0866,4967,8348,77810,61111,17312,449
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity7016057913649979151,031
Cash from Investing Activity-761-1,520-9991,211-1,7491,718188
Cash from Financing Activity-71,2383515-799-433-417
Net Cash Flow-67323-1741,590-1,5522,199803
Free Cash Flow530377269141599521538
CFO/OP99%70%79%66%98%100%91%
Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days8371998810099107
Inventory Days250312205421278294284
Days Payable829780127129143136
Cash Conversion Cycle251286225382250250255
Working Capital Days161169168242155173145
ROCE %28%25%15%14%12%15%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters57.86%57.86%57.86%51.83%51.83%51.83%51.83%51.83%51.83%51.83%51.83%51.77%
FIIs4.91%4.05%3.59%6.88%4.48%5.04%6.90%7.39%7.90%7.58%7.29%8.74%
DIIs22.45%24.17%25.23%32.83%35.37%34.80%33.27%32.86%32.63%32.99%33.36%30.44%
Public14.78%13.93%13.32%8.46%8.33%8.33%8.00%7.93%7.63%7.62%7.52%9.06%
No. of Shareholders1,61,6271,36,0211,22,3751,22,6651,22,3581,21,0751,13,7881,10,67197,15194,57891,5001,08,266

Fundamentals

Market Cap₹ 49,333 Cr.
Current Price₹ 2,990
Stock P/E43.1
Book Value₹ 629
ROCE15.1 %
ROE10.7 %
Dividend Yield0.67 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)18%
Compounded Profit Growth (TTM)49%
Consolidated figures.
Valuation
Market capRs 47,342 Cr
Enterprise valueRs 43,575 Cr
P/E (TTM)41.94x
Price to book5.95x
Price to sales7.04x
EV / EBITDA21.29x
EV / EBIT27.02x
EV / sales6.48x
Price to cash flow130.07x
Earnings yield2.38%
P/E, 3-year average37.26x
P/B, 3-year average5.67x
Profitability
Operating margin (excl. other income)28.27%
Operating margin (incl. other income)33.35%
EBITDA margin30.43%
Pre-tax margin23.59%
Net profit margin16.78%
Net margin, latest quarter17.61%
ROE10.33%
ROCE14.04%
ROA9.40%
ROE, 3-year average16.59%
ROCE, 3-year average22.30%
ROA, 3-year average15.05%
ROIC (approx.)28.49%
Tax rate25.94%
Other income / net worth2.31%
Growth
Sales growth (latest year)-17.64%
Profit growth (latest year)-35.54%
Sales CAGR, 3 years11.24%
Profit CAGR, 3 years0.35%
Sales growth QoQ3.30%
Profit growth QoQ-13.56%
Sales growth YoY (latest quarter)19.57%
Profit growth YoY (latest quarter)47.09%
Per share
EPS (TTM)Rs 68.54
EPS (latest year)Rs 47.42
EPS (latest quarter)Rs 19.24
EPS, 3-year averageRs 60.70
Book value per shareRs 483.22
Sales per shareRs 408.33
Cash flow per shareRs 22.10
Free cash flow per shareRs 32.67
Efficiency
Asset turnover0.41x
Fixed asset turnover2.31x
Inventory turnover1.01x
Inventory days362 days
Debtor days88 days
Debtors turnover4.16x
Creditor days136 days
Cash conversion cycle255 days
Working capital days145 days
Leverage
Total debtRs 4 Cr
Cash and bankRs 3,771 Cr
Net debtRs -3,766 Cr
Debt to equity0.00x
Net debt / EBITDA-1.84x
Interest coverage61.70x
Current ratio (filing 2026-03-31)4.68x
Quick ratio (filing 2026-03-31)3.60x
Trade payables (filing 2026-03-31)Rs 834 Cr
Owners' fund to total sources90.67%
Debt to assets0.05%
Cash flow
Cash from Operating Activity (latest year)Rs 364 Cr
Cash from Investing Activity (latest year)Rs 1,211 Cr
Cash from Financing Activity (latest year)Rs 15 Cr
Net Cash Flow (latest year)Rs 1,590 Cr
Free cash flow (latest year)Rs 538 Cr
FCFE (approx.: FCF + change in debt)Rs 538 Cr
Cash from ops / profit, 5 years0.91x
Sales to cash flow9.96x
Statement figures
Net sales (TTM)Rs 6,725 Cr
Net sales (latest year)Rs 3,625 Cr
Sales (latest quarter)Rs 1,800 Cr
Operating profit excl. other income (latest year)Rs 1,025 Cr
Operating profit (latest quarter)Rs 489 Cr
Other income (TTM)Rs 296 Cr
EBITDA (TTM)Rs 2,047 Cr
PBDT (TTM)Rs 2,021 Cr
Profit before tax (TTM)Rs 1,587 Cr
Tax (latest year)Rs 274 Cr
Net profit (TTM)Rs 1,129 Cr
Net profit (latest year)Rs 781 Cr
Net profit (latest quarter)Rs 317 Cr
Depreciation (TTM)Rs 434 Cr
Depreciation (latest quarter)Rs 111 Cr
Interest (TTM)Rs 26 Cr
Cost of goods sold (latest year)Rs 1,964 Cr
Total expenditure (latest year)Rs 2,600 Cr
Total income (latest year)Rs 3,809 Cr
Share capitalRs 16 Cr
ReservesRs 7,942 Cr
Shareholders' fundsRs 7,959 Cr
Total assetsRs 8,778 Cr
Net blockRs 1,571 Cr
Capital work in progressRs 177 Cr
ReceivablesRs 871 Cr
InventoryRs 1,945 Cr
Other liabilitiesRs 814 Cr
Shares outstanding (crore)16.47
Ownership
Promoter holding51.77% (-0.06 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 41.9 is at the 85th percentile of its own 3.4-year range (median 36.7, low 22.6, high 48.7).
P/B 5.95 is at the 66th percentile (median 5.01).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodGLANDNifty 50Difference
1 week-0.8%-2.8% +2.0 pts
1 month-0.0%-6.8% +6.8 pts
3 months+16.7%-7.6% +24.4 pts
6 months+69.5%+0.4% +69.1 pts
1 year+45.7%-9.9% +55.6 pts
2 years+55.7%-13.6% +69.3 pts
3 years+71.6%+14.2% +57.4 pts
5 years-22.9%+27.9% -50.8 pts
138 mutual fund schemes hold about ₹12,303 Cr. Over three months 26 bought more and 66 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Mid Cap Fund1.62%1,751 -11%
SBI Large & Midcap Fund2.17%920 -4%
Nippon India Growth Mid Cap Fund1.55%808 -7%
Mirae Asset Large & Midcap Fund1.23%564 -35%
Nippon India Small Cap Fund0.64%529 -6%
HDFC Large & Mid Cap Fund1.33%404 -4%
ICICI Pru India Opp Fund1.01%387 -47%
DSP Small Cap Fund1.75%380 -10%
Canara Rob Small Cap Fund2.39%351 +7%
Mirae Asset Midcap Fund1.67%349 -33%
Nippon India Multi Cap Fund0.61%345 -4%
SBI Contra Fund0.68%321 -1%
Nippon India ELSS Tax Saver Fund2.16%317 +0%
Axis Small Cap Fund0.87%275 -7%
UTI Flexi Cap Fund1.05%253 +4%
Mirae Asset ELSS Tax Saver Fund0.94%247 -55%
Sundaram Mid Cap Fund1.63%242 -9%
Sundaram Mid Cap Fund1.63%237 -9%
Nippon India Pharma Fund2.44%231 -5%
DSP Healthcare Fund5.98%230 -22%
Mirae Asset Large Cap Fund0.52%203 -39%
SBI Healthcare Opp Fund2.99%173 -15%
HDFC Multi Cap Fund0.72%149 -3%
HDFC Manufacturing Fund1.37%145 -31%
UTI Mid Cap Fund1.10%141 -11%

Red flags

F-score 4 of 8
lookInventory outrunning sales Inventory grew 64% vs sales -18% in 2026
lookRegulator order or action Regulator order or action 2026-07-16: Gland Pharma Limited has informed the Exchange about Action(s) taken or orders passed
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2026-02-09A. JAYATHEERTHAEmployees/Designated Employesell100Rs 0.02 CrMarket Sale
2026-02-02A. JAYATHEERTHAEmployees/Designated Employesell306Rs 0.06 CrMarket Sale
2026-02-02P LAKSHMI NARAYANAEmployees/Designated Employesell800Rs 0.15 CrMarket Sale
2025-11-21P LAKSHMI NARAYANAEmployees/Designated Employesell300Rs 0.05 CrMarket Sale
2025-09-26A. JAYATHEERTHAEmployees/Designated Employesell191Rs 0.04 CrMarket Sale
2025-09-23A. JAYATHEERTHAEmployees/Designated Employesell325Rs 0.07 CrMarket Sale
2025-02-26S SRINIVASA RAOEmployees/Designated Employeother2,800Rs 0.15 CrESOP
2024-06-27S SRINIVASA RAOEmployees/Designated Employesell1,950Rs 0.35 CrMarket Sale
2024-06-27RONG WUEmployees/Designated Employesell5,792Rs 1.04 CrMarket Sale
2024-06-27P B Ravindra VarmaEmployees/Designated Employesell1,950Rs 0.35 CrMarket Sale
2024-06-27BH LENIN KUMAR RAJAEmployees/Designated Employesell1,400Rs 0.25 CrMarket Sale
2024-06-25T.V. SATYANARAYANAEmployees/Designated Employesell2,250Rs 0.41 CrMarket Sale
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹1,800 Cr +19.5% vs Jun 2025. Net profit ₹317 Cr +47.4%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-08-11Dividend - Rs 20 Per Sh
2025-08-14Dividend - Rs 18 Per Share
2024-08-16Annual General Meeting/Dividend - Rs 20 Per Share
2021-08-06 Annual General Meeting
DateTypeWhat it says
2026-10-01ResignationResignation of Director/KMP/SMP
2026-10-01General UpdatesInvestment by Gland Pharma Limited in Gland Pharma USA Inc. and Investment by Gland Pharma USA Inc. into Novelstar Pharma Inc.
2026-10-01Board meeting outcomeOutcome of Board Meeting held on October 01, 2026.
2026-09-13General UpdatesAcquisition of 100% of the equity share capital of Gland Pharma USA Inc. , a wholly-owned step down subsidiary of the Company, from Gland Pharma Inter...
2026-09-13Board meeting outcomeOutcome of Board Meeting held on September 13, 2026.
2026-09-13General UpdatesAllotment of 44,193 Equity Shares on exercise of ESOPs
2026-09-13ESOP grantOptions to purchase securities
2026-09-13General UpdatesBoard comments on fines levied by the Exchanges
2026-09-10Concall / analyst meetSchedule of meet
2026-09-08Concall / analyst meetSchedule of meet
2026-09-04Concall / analyst meetSchedule of meet
2026-09-01General UpdatesGeneral Updates
2026-08-31Concall / analyst meetSchedule of meet
2026-08-26Shareholder meetingVoting results.
2026-08-25Shareholder meetingProceedings of Annual General Meeting held on August 25, 2026
2026-08-23Concall / analyst meetSchedule of meet
2026-08-17Concall / analyst meetTranscript
2026-08-14AppointmentAppointment of Mr Deepak Sapra as Chief Executive Officer of the company w.e.f. November 16, 2026.
2026-08-10Concall / analyst meetLink of Recording
2026-08-10Concall / analyst meetSchedule of meet
2026-08-10Investor PresentationInvestor Presentation
2026-08-10Press ReleaseA press release dated August 10, 2026, titled "Press Release on Q1FY27 Financial Results".
2026-08-10Board meeting outcomeGland Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-08-09Press ReleaseA press release dated August 09, 2026, titled "Gland Pharma Announces Strategic CDMO Partnership with aGlobal Pharmaceutical Company".
2026-08-09Arrangements for strategic, Arrangements for strategic, technical, manufacturing, or marketing tie up
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Gland Pharma Ltd?

Gland Pharma Ltd (GLAND) has a market capitalisation of Rs 49,333 Cr. at the 2026-10-01 close.

What is the P/E ratio of Gland Pharma Ltd?

Gland Pharma Ltd trades at a P/E of 43.1 on trailing twelve-month profit, at the 2026-10-01 close.

What were Gland Pharma Ltd's latest quarterly results?

In the Jun 2026 quarter, Gland Pharma Ltd sales was Rs 1,800 Cr (+19.5% vs Jun 2025) and net profit was Rs 317 Cr.

What is the 52-week high and low of Gland Pharma Ltd?

The 52-week high is Rs 3,042.00 and the 52-week low is Rs 1,573.60.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03